| Name | Title | Contact Details |
|---|
Accessity Corp. is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
USMD is a publicly held (NASDAQ: USMD), physician-led integrated healthcare system committed to exemplary patient care. Headquartered in Irving, Texas, USMD serves the Dallas-Fort Worth metropolitan area with more than 250 physicians and associate practitioners, and provides healthcare services to patients in just under 20 different specialties at its hospitals, nine cancer treatment centers and nearly 70 physician clinics. For more information about USMD, visit www.usmd.com.
Pharma-Med Inc. is a Allentown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
As a leading national healthcare solutions organization, Premier, Inc. collaborates with healthcare organizations to improve supply chain management, decrease healthcare costs, integrate data and improve the health of communities. As an industry leader, Premier has created one of the most comprehensive database of actionable data, best practices and cost reduction strategies. We enable our members to collaborate easily and efficiently improve their quality outcomes, while reducing costs. By engaging members and revealing new opportunities, we empower our alliance to improve performance like no one else in healthcare can.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.